Acumen Pharmaceuticals (ABOS) Non Operating Income (2020 - 2026)
Acumen Pharmaceuticals recorded quarterly Non Operating Income of $412000.0 in Q1 2026, up 575.41% quarter-over-quarter from $61000.0 in Q4 2025, and up 743.75% year-over-year from $48829.6 in Q1 2025.
Acumen Pharmaceuticals' Non Operating Income history runs 7 years deep, the most recent figure standing at $412000.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 743.75% year-over-year to $412000.0; the TTM figure through Mar 2026 stood at $1.2 million (up 847.83% YoY), while the FY2025 annual figure was $2.5 million, up 1753.64% from the prior year.
- Non Operating Income came in at $412000.0 for Q1 2026 at Acumen Pharmaceuticals, up from $61000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3.1 million in Q3 2023 to a low of -$1.0 million in Q4 2022.
- A 5-year average of $197352.9 and a median of -$4000.0 in 2023 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income jumped 154200.0% in 2023 and tumbled 1250.0% in 2024, its largest moves.
- Acumen Pharmaceuticals' Non Operating Income stood at -$1.0 million in 2022, then soared by 97.92% to -$21000.0 in 2023, then plunged by 195.24% to -$62000.0 in 2024, then surged by 198.39% to $61000.0 in 2025, then soared by 575.41% to $412000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $412000.0, $61000.0, and -$69000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | 412,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 412,000.00 |
| Dec 31, 2025 | 61,000.00 |
| Sep 30, 2025 | -69,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | -64,000.00 |
| Dec 31, 2024 | -62,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | -68,000.00 |
| Mar 31, 2024 | -54,000.00 |
| Dec 31, 2023 | -21,000.00 |
| Sep 30, 2023 | 3.08 Mn |
| Jun 30, 2023 | -16,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | -1.01 Mn |
| Sep 30, 2022 | -2,000.00 |
| Jun 30, 2022 | 260,000.00 |
| Mar 31, 2022 | 77,000.00 |
| Dec 31, 2021 | 81.14 Mn |
| Sep 30, 2021 | 33,000.00 |
| Jun 30, 2021 | 19,000.00 |
| Mar 31, 2021 | 9,000.00 |
| Dec 31, 2020 | 586,000.00 |